Aristolochic acid exposure in Romania and implications for renal cell carcinoma

British Journal of Cancer

Volumn 114, Issue 1, 2016, Pages 76-80

  Turesky, Robert J ^a   Yun, Byeong Hwa ^a   Brennan, Paul ^b   Mates, Dana ^c   Jinga, Viorel ^d   Harnden, Patricia ^e   Banks, Rosamonde E ^e   Blanche, Helene ^f   Bihoreau, Marie Therese ^g   Chopard, Priscilia ^b   Letourneau, Louis ^h   Lathrop, G Mark ^h   Scelo, Ghislaine ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Romania)

^d CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f FONDATION JEAN DAUSSET CEPH   (France)

^g CENTRE NATIONAL DE GÉNOTYPAGE   (France)

^h MCGILL UNIVERSITY   (Canada)

Author keywords

aristolochic acid; DNA adducts; environment; mutational signatures; renal cell carcinoma

Indexed keywords

7 (DEOXYADENOSIN N 6 YL)ARISTOLACTAM; ARISTOLOCHIC ACID; ARISTOLOLACTAM; DNA BASE; UNCLASSIFIED DRUG; 7-(DEOXYADENOSIN-N(6)-YL)ARISTOLACTAM I; ARISTOLOCHIC ACID I; DEOXYADENOSINE DERIVATIVE;

ARTICLE; ASIAN; BALKAN PENINSULA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ADDUCT; ELECTROSPRAY MASS SPECTROMETRY; ENVIRONMENTAL EXPOSURE; FOOD CONTAMINATION; GENE MUTATION; HERBAL MEDICINE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY CORTEX; KIDNEY PARENCHYMA; POPULATION; PRIORITY JOURNAL; ROMANIA; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; CHEMICALLY INDUCED; GENETICS; KIDNEY TUMOR; MUTATION;

ARISTOLOCHIC ACIDS; CARCINOMA, RENAL CELL; DEOXYADENOSINES; HUMANS; KIDNEY NEOPLASMS; MUTATION; ROMANIA; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84954389186     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.402     Document Type: Article

References (17)

1. Attaluri S, Bonala RR, Yang IY, Lukin MA, Wen Y, Grollman AP, Moriya M, Iden CR, Johnson F. (2010). DNA adducts of aristolochic acid II: total synthesis and site-specific mutagenesis studies in mammalian cells. Nucleic Acids Res. 38(1): 339-352.
2. Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, Pu YS, Grollman AP. (2012). Aristolochic acid-Associated urothelial cancer in Taiwan. Proc Natl Acad Sci USA. 109(21): 8241-8246.
3. Debelle FD, Vanherweghem JL, Nortier JL. (2008). Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 74(2): 158-169.
4. Gluhovschi G, Margineanu F, Kaycsa A, Velciov S, Gluhovschi C, Bob F, Petrica L, Bozdog G, Dumitru S, Olosz E, Modalca M. (2010). Therapeutic remedies based on Aristolochia clematitis in the main foci of Balkan endemic nephropathy in Romania. Nephron Clin Pract. 116(1): c36-c46.
5. Grollman AP. (2013). Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen. 54(1): 1-7.
6. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelic M, Jelakovic B. (2007). Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA. 104(29): 12129-12134.
7. Hoang ML, Chen CH, Sidorenko VS, He J, Dickman KG, Yun BH, Moriya M, Niknafs N, Douville C, Karchin R, Turesky RJ, Pu YS, Vogelstein B, Papadopoulos N, Grollman AP, Kinzler KW, Rosenquist TA. (2013). Mutational signature of aristolochic acid exposure as revealed by wholeexome sequencing. Sci Transl Med. 5(197): 197ra102.
8. Jelakovic B, Castells X, Tomic K, Ardin M, Karanovic S, Zavadil J. (2015). Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid. Int J Cancer. 136(12): 2967-2972.
9. Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, Weng WH, Siew EY, Liu Y, Heng HL, Chong SC, Gan A, Tay ST, Lim WK, Cutcutache I, Huang D, Ler LD, Nairismagi ML, Lee MH, Chang YH, Yu KJ, Chan-On W, Li BK, Yuan YF, Qian CN, Ng KF, Wu CF, Hsu CL, Bunte RM, Stratton MR, Futreal PA, Sung WK, Chuang CK, Ong CK, Rozen SG, Tan P, Teh BT. (2013). Genome-wide mutational signatures of aristolochic Acid and its application as a screening tool. Sci Transl Med. 5(197): 197ra101.
10. Scelo G, Riazalhosseini Y, Greger L, Letourneau L, Gonzalez-Porta M, Wozniak MB, Bourgey M, Harnden P, Egevad L, Jackson SM, Karimzadeh M, Arseneault M, Lepage P, How-Kit A, Daunay A, Renault V, Blanche H, Tubacher E, Sehmoun J, Viksna J, Celms E, Opmanis M, Zarins A, Vasudev NS, Seywright M, Abedi-Ardekani B, Carreira C, Selby PJ, Cartledge JJ, Byrnes G, Zavadil J, Su J, Holcatova I, Brisuda A, Zaridze D, Moukeria A, Foretova L, Navratilova M, Mates D, Jinga V, Artemov A, Nedoluzhko A, Mazur A, Rastorguev S, Boulygina E, Heath S, Gut M, Bihoreau MT, Lechner D, Foglio M, Gut IG, Skryabin K, Prokhortchouk E, Cambon-Thomsen A, Rung J, Bourque G, Brennan P, Tost J, Banks RE, Brazma A, Lathrop GM. (2014). Variation in genomic landscape of clear cell renal cell carcinoma across Europe. Nat Commun 5: 5135.
11. Schmeiser HH, Nortier JL, Singh R, da Costa GG, Sennesael J, Cassuto-Viguier E, Ambrosetti D, Rorive S, Pozdzik A, Phillips DH, Stiborova M, Arlt VM. (2014). Exceptionally long-Term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int J Cancer. 135(2): 502-507.
12. Sidorenko VS, Yeo JE, Bonala RR, Johnson F, Schärer OD, Grollman AP. (2012). Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. Nucleic Acids Res. 40(6): 2494-2505.
13. Stefanovic V, Polenakovic M. (2009). Fifty years of research in Balkan endemic nephropathy: where are we now?. Nephron Clin Pract. 112(2): c51-c56.
14. Yun BH, Sidorenko VS, Rosenquist TA, Dickman KG, Grollman AP, Turesky RJ. (2015). New approaches for biomonitoring exposure to the human carcinogen aristolochic acid. Toxicol Res 4: 763-776.
15. Yun BH, Rosenquist TA, Nikolic J, Dragicevic D, Tomic K, Jelakovic B, Dickman KG, Grollman AP, Turesky RJ. (2013). Human formalin-fixed paraffin-embedded tissues: an untapped specimen for biomonitoring of carcinogen DNA adducts by mass spectrometry. Anal Chem. 85(9): 4251-4258.
16. Yun BH, Rosenquist TA, Sidorenko V, Iden CR, Chen CH, Pu YS, Bonala R, Johnson F, Dickman KG, Grollman AP, Turesky RJ. (2012). Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-Trap mass spectrometry. Chem Res Toxicol. 25(5): 1119-1131.
17. Yun BH, Yao L, Jelakovic B, Nikolic J, Dickman KG, Grollman AP, Rosenquist TA, Turesky RJ. (2014). Formalin-fixed paraffin-embedded tissue as a source for quantitation of carcinogen DNA adducts: aristolochic acid as a prototype carcinogen. Carcinogenesis. 35(9): 2055-2061.